Georgia

Georgia

Hepatitis B

Download HBV data

Prevalence of chronic HBV (HBsAg+)

National
Download
Value (%) Year Type Source
1.48 (1.46 - 1.50) 2019 Modelled IHME
1.49 (1.48 - 1.51) 2018 Modelled IHME
1.51 (1.49 - 1.53) 2017 Modelled IHME
1.54 (1.52 - 1.56) 2016 Modelled IHME
1.57 (1.55 - 1.59) 2015 Modelled IHME
1.61 (1.59 - 1.63) 2014 Modelled IHME
1.65 (1.63 - 1.67) 2013 Modelled IHME
1.69 (1.67 - 1.71) 2012 Modelled IHME
1.73 (1.71 - 1.75) 2011 Modelled IHME
1.76 (1.74 - 1.78) 2010 Modelled IHME
1.79 (1.76 - 1.81) 2009 Modelled IHME
1.81 (1.79 - 1.83) 2008 Modelled IHME
1.83 (1.81 - 1.85) 2007 Modelled IHME
1.85 (1.82 - 1.87) 2006 Modelled IHME
1.87 (1.84 - 1.90) 2005 Modelled IHME
1.9 (1.87 - 1.93) 2004 Modelled IHME
1.93 (1.90 - 1.96) 2003 Modelled IHME
1.97 (1.93 - 2) 2002 Modelled IHME
1.99 (1.95 - 2.03) 2001 Modelled IHME
2 (1.96 - 2.04) 2000 Modelled IHME
2 (1.96 - 2.03) 1999 Modelled IHME
1.99 (1.95 - 2.02) 1998 Modelled IHME
1.97 (1.94 - 2.01) 1997 Modelled IHME
1.96 (1.93 - 2) 1996 Modelled IHME
1.95 (1.92 - 1.99) 1995 Modelled IHME
1.95 (1.91 - 1.98) 1994 Modelled IHME
1.94 (1.91 - 1.98) 1993 Modelled IHME
1.94 (1.90 - 1.98) 1992 Modelled IHME
1.94 (1.90 - 1.98) 1991 Modelled IHME
1.93 (1.89 - 1.98) 1990 Modelled IHME
2.09 (1.48 - 2.83) 2015 Modelled WHO
2.9 (2.38 - 3.51) 2017 Survey/reported Kasradze et al, 2017
2.64 (2.22 - 3.14) 2013 Modelled Schweitzer et al, 2015
Showing out of
Show more
Children under-5 years
Download
Value (%) Year Type Source
0.24 (0.21 - 0.28) 2019 Modelled IHME
0.26 (0.23 - 0.28) 2018 Modelled IHME
0.26 (0.23 - 0.29) 2017 Modelled IHME
0.26 (0.23 - 0.29) 2016 Modelled IHME
0.26 (0.22 - 0.30) 2015 Modelled IHME
0.26 (0.22 - 0.30) 2014 Modelled IHME
0.27 (0.23 - 0.31) 2013 Modelled IHME
0.28 (0.24 - 0.32) 2012 Modelled IHME
0.29 (0.24 - 0.33) 2011 Modelled IHME
0.31 (0.25 - 0.34) 2010 Modelled IHME
0.34 (0.29 - 0.38) 2009 Modelled IHME
0.41 (0.35 - 0.45) 2008 Modelled IHME
0.49 (0.43 - 0.54) 2007 Modelled IHME
0.58 (0.51 - 0.64) 2006 Modelled IHME
0.67 (0.58 - 0.75) 2005 Modelled IHME
0.76 (0.64 - 0.85) 2004 Modelled IHME
0.85 (0.70 - 0.98) 2003 Modelled IHME
0.95 (0.75 - 1.11) 2002 Modelled IHME
1.05 (0.80 - 1.23) 2001 Modelled IHME
1.13 (0.86 - 1.33) 2000 Modelled IHME
1.21 (0.94 - 1.41) 1999 Modelled IHME
1.31 (1.05 - 1.49) 1998 Modelled IHME
1.39 (1.16 - 1.56) 1997 Modelled IHME
1.45 (1.24 - 1.61) 1996 Modelled IHME
1.47 (1.27 - 1.64) 1995 Modelled IHME
1.47 (1.27 - 1.63) 1994 Modelled IHME
1.47 (1.26 - 1.63) 1993 Modelled IHME
1.46 (1.24 - 1.62) 1992 Modelled IHME
1.45 (1.19 - 1.62) 1991 Modelled IHME
1.42 (1.13 - 1.63) 1990 Modelled IHME
0.26 (0.16 - 0.42) 2015 Modelled WHO
Showing out of
Show more

Percent of liver cancer deaths attributable to HBV

National
Download
Value (%) Year Type Source
22 (16 - 30) 2019 Modelled IHME
22 (16 - 30) 2018 Modelled IHME
22 (16 - 30) 2017 Modelled IHME
22 (16 - 30) 2016 Modelled IHME
22 (16 - 30) 2015 Modelled IHME
23 (17 - 30) 2014 Modelled IHME
23 (17 - 31) 2013 Modelled IHME
23 (17 - 31) 2012 Modelled IHME
23 (17 - 31) 2011 Modelled IHME
23 (17 - 31) 2010 Modelled IHME
23 (17 - 31) 2009 Modelled IHME
23 (17 - 31) 2008 Modelled IHME
23 (17 - 31) 2007 Modelled IHME
23 (17 - 31) 2006 Modelled IHME
23 (16 - 31) 2005 Modelled IHME
23 (16 - 31) 2004 Modelled IHME
23 (17 - 32) 2003 Modelled IHME
24 (17 - 33) 2002 Modelled IHME
24 (17 - 33) 2001 Modelled IHME
24 (17 - 33) 2000 Modelled IHME
24 (17 - 33) 1999 Modelled IHME
24 (17 - 34) 1998 Modelled IHME
24 (17 - 33) 1997 Modelled IHME
24 (17 - 33) 1996 Modelled IHME
23 (17 - 32) 1995 Modelled IHME
23 (17 - 32) 1994 Modelled IHME
23 (16 - 31) 1993 Modelled IHME
23 (17 - 31) 1992 Modelled IHME
23 (16 - 31) 1991 Modelled IHME
23 (16 - 31) 1990 Modelled IHME
Showing out of
Show more
Technical notes

Coverage of HepB birth dose

Newborns
Download
Value (%) Year Type Source
97 2018 Survey/reported WHO/UNICEF
94 2017 Survey/reported WHO/UNICEF
94 2016 Survey/reported WHO/UNICEF
93 2015 Survey/reported WHO/UNICEF
95 2014 Survey/reported WHO/UNICEF
80 2013 Survey/reported WHO/UNICEF
92 2012 Survey/reported WHO/UNICEF
93 2011 Survey/reported WHO/UNICEF
95 2010 Survey/reported WHO/UNICEF
73 2009 Survey/reported WHO/UNICEF
99 2008 Survey/reported WHO/UNICEF
99 2007 Survey/reported WHO/UNICEF
97 2006 Survey/reported WHO/UNICEF
93 2005 Survey/reported WHO/UNICEF
92 2004 Survey/reported WHO/UNICEF
90 2003 Survey/reported WHO/UNICEF
80 2002 Survey/reported WHO/UNICEF
69 2001 Survey/reported WHO/UNICEF
Showing out of
Show more
Technical notes

Coverage of 3-dose hepatitis B vaccine

Infants
Download
Value (%) Year Type Source
93 2018 Survey/reported WHO/UNICEF
91 2017 Survey/reported WHO/UNICEF
92 2016 Survey/reported WHO/UNICEF
94 2015 Survey/reported WHO/UNICEF
91 2014 Survey/reported WHO/UNICEF
96 2013 Survey/reported WHO/UNICEF
92 2012 Survey/reported WHO/UNICEF
89 2011 Survey/reported WHO/UNICEF
95 2010 Survey/reported WHO/UNICEF
54 2009 Survey/reported WHO/UNICEF
89 2008 Survey/reported WHO/UNICEF
94 2007 Survey/reported WHO/UNICEF
84 2006 Survey/reported WHO/UNICEF
79 2005 Survey/reported WHO/UNICEF
64 2004 Survey/reported WHO/UNICEF
48 2003 Survey/reported WHO/UNICEF
51 2002 Survey/reported WHO/UNICEF
61 2001 Survey/reported WHO/UNICEF
55 2000 Survey/reported WHO/UNICEF
Showing out of
Show more

Number of needles/syringes per PWID per year

Percent of PWID accessing OST

People who inject drugs (PWID)
Download
Value (%) Year Type Source
3.9 (3.10 - 4.80) 2015 Survey/reported Curatio International Foundation, 2015
HBV National Action Plan
Eligible for HBV generic medicines
Year of birth dose introduction
2001
HepB birth dose policy
Yes
HCV National Action Plan
HCV elimination goal
Year of HCV elimination goal
2030
HCV testing policy
Risk-based, Birth cohort
Eligible for HCV generic medicines
At least one needle-syringe exchange program (NSP) operational
Yes
At least one opioid substitution therapy (OST) program operational
Yes
NSP in at least one prison
No
OST in at least one prison
No
% of substance use disorder facilities offering hepatitis testing
Most (61-100%)
% of substance use disorder facilities offering hepatitis treatment
None

Hepatitis C

Download HCV data

Prevalence of chronic HCV (RNA+/cAg)

National
Download
Value (%) Year Type Source
3.48 (2.81 - 4.24) 2019 Modelled IHME
3.5 (2.82 - 4.26) 2018 Modelled IHME
3.51 (2.83 - 4.27) 2017 Modelled IHME
3.49 (2.84 - 4.26) 2016 Modelled IHME
3.48 (2.85 - 4.25) 2015 Modelled IHME
3.54 (2.93 - 4.29) 2014 Modelled IHME
3.68 (3.08 - 4.40) 2013 Modelled IHME
3.85 (3.26 - 4.54) 2012 Modelled IHME
4 (3.38 - 4.67) 2011 Modelled IHME
4.06 (3.44 - 4.75) 2010 Modelled IHME
4.06 (3.44 - 4.75) 2009 Modelled IHME
4.06 (3.44 - 4.75) 2008 Modelled IHME
4.06 (3.44 - 4.74) 2007 Modelled IHME
4.06 (3.43 - 4.75) 2006 Modelled IHME
4.06 (3.41 - 4.75) 2005 Modelled IHME
4.08 (3.43 - 4.76) 2004 Modelled IHME
4.11 (3.46 - 4.80) 2003 Modelled IHME
4.14 (3.48 - 4.86) 2002 Modelled IHME
4.17 (3.49 - 4.91) 2001 Modelled IHME
4.18 (3.50 - 4.93) 2000 Modelled IHME
4.14 (3.46 - 4.85) 1999 Modelled IHME
4.03 (3.36 - 4.76) 1998 Modelled IHME
3.9 (3.21 - 4.63) 1997 Modelled IHME
3.77 (3.08 - 4.53) 1996 Modelled IHME
3.67 (2.96 - 4.47) 1995 Modelled IHME
3.61 (2.92 - 4.41) 1994 Modelled IHME
3.55 (2.88 - 4.35) 1993 Modelled IHME
3.5 (2.82 - 4.29) 1992 Modelled IHME
3.46 (2.77 - 4.25) 1991 Modelled IHME
3.43 (2.76 - 4.25) 1990 Modelled IHME
5.4 (4.60 - 6.40) 2015 Survey/reported Hagan et al, 2015
4.2 (3 - 4.20) 2015 Modelled Blach et al, 2017
Showing out of
Show more

Prevalence of anti-HCV

National
Download
Value (%) Year Type Source
8.9 2018 Survey/reported Averhoff A et al, 2020
6.7 (5.60 - 7.30) 2014 Modelled Gower et al, 2014
7.7 (6.70 - 8.90) 2015 Survey/reported Hagan et al, 2015
Showing out of
Show more
People who inject drugs (PWID)
Download
Value (%) Year Type Source
69.1 (58 - 80.20) 2015 Modelled Degenhardt L et al, 2017

Percent of liver cancer deaths attributable to HCV

National
Download
Value (%) Year Type Source
34 (25 - 43) 2019 Modelled IHME
34 (26 - 43) 2018 Modelled IHME
34 (26 - 43) 2017 Modelled IHME
35 (26 - 44) 2016 Modelled IHME
35 (26 - 44) 2015 Modelled IHME
35 (26 - 44) 2014 Modelled IHME
35 (26 - 44) 2013 Modelled IHME
35 (27 - 44) 2012 Modelled IHME
36 (27 - 44) 2011 Modelled IHME
36 (27 - 45) 2010 Modelled IHME
36 (27 - 45) 2009 Modelled IHME
36 (27 - 45) 2008 Modelled IHME
36 (27 - 46) 2007 Modelled IHME
37 (28 - 46) 2006 Modelled IHME
38 (28 - 46) 2005 Modelled IHME
38 (28 - 47) 2004 Modelled IHME
37 (28 - 47) 2003 Modelled IHME
37 (27 - 47) 2002 Modelled IHME
37 (28 - 47) 2001 Modelled IHME
37 (27 - 47) 2000 Modelled IHME
37 (28 - 47) 1999 Modelled IHME
37 (27 - 47) 1998 Modelled IHME
37 (28 - 47) 1997 Modelled IHME
37 (28 - 47) 1996 Modelled IHME
37 (28 - 47) 1995 Modelled IHME
37 (28 - 47) 1994 Modelled IHME
37 (28 - 47) 1993 Modelled IHME
37 (28 - 46) 1992 Modelled IHME
37 (28 - 46) 1991 Modelled IHME
37 (28 - 46) 1990 Modelled IHME
Showing out of
Show more
Technical notes

Number of needles/syringes per PWID per year

Percent of PWID accessing OST

People who inject drugs (PWID)
Download
Value (%) Year Type Source
3.9 (3.10 - 4.80) 2015 Survey/reported Curatio International Foundation, 2015
HBV National Action Plan
Eligible for HBV generic medicines
Year of birth dose introduction
2001
HepB birth dose policy
Yes
HCV National Action Plan
HCV elimination goal
Year of HCV elimination goal
2030
HCV testing policy
Risk-based, Birth cohort
Eligible for HCV generic medicines
At least one needle-syringe exchange program (NSP) operational
Yes
At least one opioid substitution therapy (OST) program operational
Yes
NSP in at least one prison
No
OST in at least one prison
No
% of substance use disorder facilities offering hepatitis testing
Most (61-100%)
% of substance use disorder facilities offering hepatitis treatment
None

Overview

HCV elimination goal
Year of goal
2030

Prevalence (national)

Modelled

HBV (HBsAg+)
1.48 (%)
2019
(1.46 - 1.5(%))
IHME
HCV (RNA/cAg+)
3.48 (%)
2019
(2.81 - 4.24(%))
IHME

Survey/surveillance

HBV (HBsAg+)
2.9 (%)
2017
(2.38 - 3.51(%))
Kasradze et al, 2017
HCV (anti-HCV)
8.9 (%)
2018
Averhoff A et al, 2020

Hepatitis related deaths (national)

Modelled

HBV
367
2019
(268 - 493)
IHME

Survey/surveillance

No data available
HBV chart

Modelled

HCV
367
2019
(274 - 490)
IHME

Survey/surveillance

No data available
HCV chart

Prevalence < 5

HBV
0.24 (%)
2019, latest modelled
(0.21 - 0.28(%))
IHME

Prevalence PWID

HCV
69.10 (%)
2015, latest modelled
(58 - 80.20(%))
Degenhardt L et al, 2017

Birth dose vaccination coverage (national)

Survey/surveillance

HBV
97 (%)
2018
WHO/UNICEF

No. of syringes/PWID/year

Survey/surveillance

HCV
31
2015
(16 - 271)
Georgia National Centre for Disease Control and Public Health, 2015; Curatio International Foundation, 2015; Eurasia Harm Reduction Network, 2015
Eligible for HBV generic medicines
Eligible for HCV generic medicines

Resources